Insulet
$131.69Change from previous close: +0.69%Absolute change: +$0.90
At a glance
- Revenue growth
- +30.73%
- 2025 vs 2024
- Net income growth
- −40.93%
- 2025 vs 2024
- Net margin
- 9.1%
- 2024: 20.2%
Financial data
Amounts in millions of USD; per-share values in USD; shares in millions.
| Item | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Operating cash flow | 569 | 430 | 146 | 119 | — |
| Depreciation and amortization | 90.4 | 80.8 | 72.8 | 63.2 | — |
| Capital expenditure | -219 | -134 | -109 | -157 | — |
| Investing cash flow | -223 | -146 | -119 | -191 | — |
| Financing cash flow | -595 | -28.0 | -13.6 | -40.3 | — |
| Share repurchases | -59.6 | 0.0 | 0.0 | — | — |
| Debt issued | 506 | 176 | 0.0 | 0.0 | — |
| Debt repaid | -1,214 | -216 | -27.0 | -39.8 | — |
| Effect of exchange rates | 11.5 | -6.8 | 1.8 | -4.3 | — |
| Net change in cash | -249 | 256 | 12.6 | -112 | — |
| Free cash flow | 350 | 296 | 36.5 | -38.3 | — |